5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy

Diabetes

Volumn 57, Issue 5, 2008, Pages 1387-1393

  Gubitosi Klug, Rose A ^a,e   Talahalli, Ramaprasad ^a   Du, Yunpeng ^b   Nadler, Jerry L ^c   Kern, Timothy S ^b,d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE RECEPTOR; SUPEROXIDE; 12 15 LIPOXYGENASE; 12-15-LIPOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; EXPERIMENTAL MODEL; HISTOPATHOLOGY; LEUKOSTASIS; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CAPILLARY; RETINA DEGENERATION; RETINA GANGLION CELL; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CAPILLARY; DISEASE MODEL; ENZYMOLOGY; GENETICS; HYPERGLYCEMIA; METABOLISM; MOUSE MUTANT; PATHOLOGY; RETINA; RETINA BLOOD VESSEL;

ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; CAPILLARIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HYPERGLYCEMIA; MICE; MICE, KNOCKOUT; RETINA; RETINAL DEGENERATION; RETINAL GANGLION CELLS; RETINAL VESSELS;

EID: 48449097142     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1217     Document Type: Article

References (49)

1. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraer-meyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452, 2004
2. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP: Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 56:373-379, 2007
3. Mohr S: Potential new strategies to prevent the development of diabetic retinopathy. Expert Opin Investig Drugs 13:189-198, 2004
4. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56:337-345, 2007
5. Aguilar E, Friedlander M, Gariano RF: Endothelial proliferation in diabetic retinal microaneurysms. Arch Ophthalmol 121:740-741, 2003
6. Cogan DG, Kuwabara T: The mural cell in perspective. Arch Ophthalmol 78:133-139, 1967
7. Engerman RL: Pathogenesis of diabetic retinopathy. Diabetes 38:1203-1206, 1989
8. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47:1953-1959, 1998
9. Antonetti DA, Lieth E, Barber AJ, Gardner TW: Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 14:240-248, 1999
10. Du Y, Miller CM, Kern TS: Hyperglycemia increases mitochondrial super-oxide in retina and retinal cells. Free Radic Biol Med 35:1491-1499, 2003
11. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M: New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther 2:601-608, 2000
12. Kowluru RA: Retinal metabolic abnormalities in diabetic mouse: comparison with diabetic rat. Curr Eye Res 24:123-128, 2002
13. Zheng L, Szabo C, Kern TS: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53:2960-2967, 2004
14. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158:147-152, 2001
15. Kowluru RA, Chan PS: Oxidative stress and diabetic retinopathy [Review]. Exp Diabetes Res 2007:43603, 2007
16. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad SciUSA 96:10836-10841, 1999
17. Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T, Muia C, Caputi AP, Sautebin L: 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 85: 808-822, 2005
18. Rubin P, Mollison KW: Pharmacotherapy of diseases mediated by 5-lipoxy-genase pathway eicosanoids. Prostaglandins Other Lipid Mediat 83:188-197, 2007
19. Sharma JN, Mohammed LA: The role of leukotrienes in the pathophysiol-ogy of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology 14:10-16, 2006
20. Islam SA, Thomas SY, Hess C, Medoff BD, Means TK, Brander C, Lilly CM, Tager AM, Luster AD: The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 107:444-453, 2006
21. Lundeen KA, Sun B, Karlsson L, Fourie AM: Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol 177:3439-3447, 2006
22. Pompeia C, Freitas JJ, Kim JS, Zyngier SB, Curi R: Arachidonic acid cytotoxicity in leukocytes: implications of oxidative stress and eicosanoid synthesis. Biol Cell 94:251-265, 2002
23. Austen KF: The mast cell and the cysteinyl leukotrienes. Novartis Found Symp 271:166-175 [discussion 176-178, 198-199], 2005
24. Letts LG: Leukotrienes: role in cardiovascular physiology. Cardiovasc Clin 18:101-113, 1987
25. Osher E, Weisinger G, Limor R, Tordjman K, Stern N: The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol 252:201-206, 2006
26. Folco G, Murphy RC: Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 58:375-388, 2006
27. Gijon MA, Zarini S, Murphy RC: Biosynthesis of eicosanoids and transcel-lular metabolism of leukotrienes in murine bone marrow cells. J Lipid Res 48:716-725, 2007
28. Natarajan R, Gerrity RG, Gu JL, Lanting L, Thomas L, Nadler JL: Role of 12-lipoxygenase and oxidant stress in hyperglycaemia-induced acceleration of atherosclerosis in a diabetic pig model. Diabetologia 45:125-133, 2002
29. Bolick DT, Srinivasan S, Whetzel A, Fuller LC, Hedrick CC: 12/15 lipoxy-genase mediates monocyte adhesion to aortic endothelium in apolipopro-tein E-deficient mice through activation of RhoA and NF-kappaB. Arterioscler Thromb Vasc Biol 26:1260-1266, 2006
30. Jankun J, Aleem AM, Malgorzewicz S, Szkudlarek M, Zavodszky MI, Dewitt DL, Feig M, Selman SH, Skrzypczak-Jankun E: Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxy-genase and reduce sprout formation of human endothelial cells. Mol Cancer Ther 5:1371-1382, 2006
31. Lebeau A, Terro F, Rostene W, Pelaprat D: Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide. Cell Death Differ 11:875-884, 2004
32. Bolick DT, Orr AW, Whetzel A, Srinivasan S, Hatley ME, Schwartz MA, Hedrick CC: 12/15-lipoxygenase regulates intercellular adhesion mole-cule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 25:2301-2307, 2005
33. Li SL, Dwarakanath RS, Cai Q, Lanting L, Natarajan R: Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J Lipid Res 46:220-229, 2005
34. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL: Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest 103:1431-1436, 1999
35. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopa-thy: aminoguanidine and aspirin. Diabetes 50:1636-1642, 2001
36. Tang J, Mohr S, Du YD, Kern TS: Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans. Curr Eye Res 27:7-13, 2003
37. Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, Strauch C, Du Y, Tang J, Kern TS, Lederer MO, Brownlee M, Weiss MF, Monnier VM: Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 54:517-526, 2005
38. Kanwar M, Chan PS, Kern TS, Kowluru RA: Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dis-mutase. Invest Ophthalmol Vis Sci 48:3805-3811, 2007
39. Li JM, Shah AM: Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 287:R1014-R1030, 2004
40. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625, 2005
41. Serezani CH, Aronoff DM, Jancar S, Peters-Golden M: Leukotriene B4 mediates p47phox phosphorylation and membrane translocation in poly-unsaturated fatty acid-stimulated neutrophils. J Leukoc Biol 78:976-984, 2005
42. James AJ, Penrose JF, Cazaly AM, Holgate ST, Sampson AP: Human bronchial fibroblasts express the 5-lipoxygenase pathway. Respir Res 7:102, 2006
43. Zhang YY, Walker JL, Huang A, Keaney JF, Clish CB, Serhan CN, Loscalzo J: Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochem J 361:267-276, 2002
44. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178:3912-3917, 2007
45. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK: Leuko-triene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad SciUSA 102:17501-17506, 2005
46. Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Chakraborty R, Broderick J, Deka R, Woo D: Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum Genet 121:601-607, 2007
47. Lohmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, Meitinger T, Dichgans M: ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36:731-736, 2005
48. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R: 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59:1354-1362, 2001
49. Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, Drel VR: High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 56:2598-2608, 2007